Zobrazeno 1 - 10
of 75
pro vyhledávání: '"conjugated estrogens/bazedoxifene"'
Publikováno v:
Therapeutics and Clinical Risk Management, Vol 2016, Iss Issue 1, Pp 549-562 (2016)
Risa Kagan,1,2 Steven R Goldstein,3 James H Pickar,4 Barry S Komm5 1Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, 2East Bay Physicians Medical Group, Berkeley, CA, 3Department of Obstetrics a
Externí odkaz:
https://doaj.org/article/124aa514d78d4eecbea8f3482275a76e
Publikováno v:
Postgraduate Medicine. 130:687-693
In the 1-year phase 3 Selective estrogens, Menopause, And Response to Therapy-5 trial, cumulative amenorrhea rates with conjugated estrogens/bazedoxifene (CE/BZA) were similar to placebo and higher than with conjugated estrogens/medroxyprogesterone a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0438aa1993cb77322b67948e8c2ed232
https://doi.org/10.1080/00325481.2018.1520046
https://doi.org/10.1080/00325481.2018.1520046
Publikováno v:
Menopause (New York, N.y.)
Objective: This review describes historical development of selective estrogen receptor modulators (SERMs) and their combination with estrogens, termed a tissue selective estrogen complex (TSEC), and considers the potential for future TSEC development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::664b012cc633fe8b6ae07962c7360f1e
http://europepmc.org/articles/PMC6110370
http://europepmc.org/articles/PMC6110370
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Santiago Palacios, Kaijie Pan, Barry S. Komm, Kelly A. Ryan, Sebastian Mirkin, J. Christopher Gallagher, David L. Kendler, Ching Ray Yu
Publikováno v:
Menopause. 23:1083-1091
Conjugated estrogens/bazedoxifene reduces vasomotor symptoms and prevents postmenopausal bone loss without stimulating the breast and endometrium. We analyzed changes in bone mineral density (BMD) and bone markers using pooled data from two phase-3 t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18953b227480da60526fe4b5c9c10e80
https://doi.org/10.1097/gme.0000000000000694
https://doi.org/10.1097/gme.0000000000000694
Publikováno v:
Menopause. 22:640-649
This study aims to evaluate the effects of conjugated estrogens (CE)/bazedoxifene (BZA) on lipid and coagulation variables in a randomized, double-blind, placebo- and active-controlled phase 3 study of nonhysterectomized postmenopausal women.The Sele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9fc9d5f02ebc44c557e6e84c4139a00
https://doi.org/10.1097/gme.0000000000000362
https://doi.org/10.1097/gme.0000000000000362
Publikováno v:
Therapeutics and Clinical Risk Management
Menopausal symptoms (eg, hot flushes and vaginal symptoms) are common, often bothersome, and can adversely impact women’s sexual functioning, relationships, and quality of life. Estrogen–progestin therapy was previously considered the standard ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44f295f189afa3ea499de70e3b2a25d1
https://pubmed.ncbi.nlm.nih.gov/27103814
https://pubmed.ncbi.nlm.nih.gov/27103814
Publikováno v:
Menopause (New York, N.Y.). 24(9)
OBJECTIVE This post hoc analysis estimates time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene. METHODS In the 12-week Selective estrogens, Menopause, And Response to Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31bb88007bd47e3a87b33d74d0b064f4
https://pubmed.ncbi.nlm.nih.gov/28463874
https://pubmed.ncbi.nlm.nih.gov/28463874
Autor:
Kelly A. Ryan, Michael Messig, Sebastian Mirkin, Barry S. Komm, JoAnn V. Pinkerton, Lucy Abraham
Publikováno v:
Maturitas. 78:212-218
Objective Describe the effects of conjugated estrogens/bazedoxifene (CE/BZA), a new treatment for vasomotor symptoms (VMS) and osteoporosis prevention, on menopause-specific quality of life (MSQOL) across different patient population types in phase 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0836b23ae8ebed6166250f4b3c24a51
https://doi.org/10.1016/j.maturitas.2014.04.008
https://doi.org/10.1016/j.maturitas.2014.04.008
Autor:
Daniel A. Hussar, Daniel J. Purzycki
Publikováno v:
Journal of the American Pharmacists Association. 54:314-319
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a10dcacc6613710da9a069bc24d9c30
https://doi.org/10.1331/japha.2014.14517
https://doi.org/10.1331/japha.2014.14517